Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection

NCT04820439 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)
DRUG: Perjeta ®

Sponsor

The Affiliated Hospital of Qingdao University